Tilray Brands, Inc. (TLRY) - Q3 2026 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended February 28, 2026 (Q3 Fiscal 2026). Tilray Brands operates as a global lifestyle consumer products company with four primary segments: Cannabis, Beverage, Distribution, and Wellness. The company recently implemented a 1-for-10 reverse stock split effective December 2, 2025, and all share data in this filing has been retrospectively adjusted.
Key Financial Metrics
| Metric | Q3 2026 (3 Months) | Q3 2025 (3 Months) | YTD 2026 (9 Months) | YTD 2025 (9 Months) |
|---|---|---|---|---|
| Net Revenue | $206.7 million | $185.8 million | $633.7 million | $596.8 million |
| Gross Profit | $55.0 million | $52.0 million | $169.9 million | $172.9 million |
| Gross Margin | 26.6% | 28.0% | 26.8% | 29.0% |
| Operating Loss | $(26.4) million | $(759.9) million | $(46.6) million | $(838.7) million |
| Net Loss | $(25.2) million | $(793.5) million | $(67.2) million | $(913.5) million |
| Adjusted EBITDA | $10.7 million | $9.0 million | $29.3 million | $27.4 million |
| Cash & Equivalents | $204.6 million | $221.7 million | $204.6 million | $221.7 million |
| Restricted Cash | $44.9 million | $0 | $44.9 million | $0 |
| Total Debt (Current + Long-Term) | $152.4 million | $163.3 million | $152.4 million | $163.3 million |
Note: Debt figures exclude convertible debentures payable of $88.3 million.
Material Changes vs. Prior Period
- Revenue Growth: Consolidated net revenue increased 11% quarter-over-quarter (QoQ) and 6% year-over-year (YoY). Growth was driven by the Distribution segment (+35% QoQ) and Cannabis segment (+19% QoQ), partially offset by a decline in the Beverage segment (-24% QoQ).
- Operating Loss Improvement: The operating loss narrowed significantly to $(26.4) million from $(759.9) million in the prior year quarter. This improvement is primarily due to the absence of a $699.2 million non-cash impairment charge on goodwill and intangible assets recorded in Q3 2025.
- Segment Performance:
- Cannabis: International revenue grew 73% QoQ, driven by Germany and Poland, though price compression impacted margins. Canadian adult-use revenue grew 7% QoQ.
- Beverage: Revenue declined due to industry-wide challenges, SKU rationalization under "Project 420," and the impact of new U.S. federal legislation restricting hemp-derived Delta-9 products.
- Distribution: Revenue surged due to favorable foreign exchange impacts and a focus on higher-velocity SKUs.
- Stock-Based Compensation: Increased significantly to $13.7 million (Q3 2026) from $4.0 million (Q3 2025) due to the recognition of performance-based awards.
Guidance, Outlook, and Risks
- Strategic Acquisitions (Subsequent Events): Following the quarter end, Tilray announced the acquisition of BrewDog assets in the UK, Australia, and the U.S. for a total consideration of approximately $54 million. This aligns with the strategy to expand the beverage platform internationally.
- Cost Optimization: Management confirmed the completion of the $33 million "Project 420" synergy plan for the beverage segment. Focus remains on disciplined cost management and margin improvement.
- Regulatory Risks:
- U.S. Hemp Legislation: New federal legislation enacted in late 2025 restricts the production and sale of hemp-derived Delta-9 products, effective November 2026. This poses a risk to the beverage segment's HD-D9 product line.
- Cannabis Rescheduling: The company is monitoring U.S. federal rescheduling of cannabis, which could create opportunities for medical-grade products but introduces regulatory complexity.
- Legal Proceedings: A significant lawsuit filed by MMIRF, LLC (an assignee of MedMen claims) seeks damages in excess of $1.0 billion. Management intends to vigorously defend the claim and has not accrued a liability as a loss is not currently deemed probable or estimable.
- Capital Structure: The company continues to opportunistically exchange equity for its TLRY 27 convertible notes. As of February 28, 2026, $100 million principal remains outstanding on these notes.
Investor Verification Checklist
- BrewDog Integration: Verify the timeline and regulatory approval status for the BrewDog U.S. and international asset acquisitions announced in March 2026.
- HD-D9 Impact: Assess the specific revenue exposure of the beverage segment to the new U.S. federal ban on hemp-derived Delta-9 products effective November 2026.
- MMIRF Litigation: Monitor developments in the $1.0 billion lawsuit regarding MedMen fiduciary duties to evaluate potential future accruals.
- International Cannabis Margins: Review the sustainability of international cannabis revenue growth given the noted price compression in key markets like Germany.
- Debt Covenants: Confirm compliance with the minimum consolidated trailing-twelve-months EBITDA and liquidity covenants added to the ABC Group Credit Agreement in July 2025.